Drug Trial Radar · NCT06208488
A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Nov 22, 2023
Primary completion
Sep 17, 2024
Study completion Sep 28, 2024
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.
Conditions
- Healthy Adult Participants
Interventions
Gefurulimab PFS-SDDrug
Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
Gefurulimab AIDrug
Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time zero to the last measurable concentration (AUClast)Time frame: Day 1 up to early discontinuation or Day 92
- Area under the serum concentration-time curve from time zero to time infinity (AUCinf)Time frame: Day 1 up to early discontinuation or Day 92
- Maximum (peak) concentration observed after study intervention administration (Cmax)Time frame: Day 1 up to early discontinuation or Day 92
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Toronto, Ontario, Canada
Research Site
Laval, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.